Nuchev Limited (ASX:NUC) shares climbed 20% to AUD 0.12 on 25 June 2026, providing some relief for long-suffering shareholders in this premium goat milk nutrition company. The stock's market capitalisation currently stands at approximately AUD 18.82 million. However, it is important to set today's gain in its proper context — NUC's 12-month return remains firmly negative at -25%, reflecting an extended period of value erosion that today's bounce only partially addresses.

The current AUD 0.12 price represents a dramatic contrast from the company's IPO price of AUD 2.60 at listing, underscoring the scale of the journey NUC shareholders have endured since the company debuted on the ASX.

What Just Happened? The Recent Update

Nuchev is a Melbourne-based health and nutrition company specialising in goat milk-based formula and nutritional products, sold primarily under the Oli6 brand across Australia, China, and Vietnam. The company also distributes a range of European health brands in Australia and New Zealand through its bWellness subsidiary, which was acquired in 2024 for AUD 7 million.

The company's most recent half-year financial results showed a net loss of AUD 2.24 million — a deterioration from the AUD 1.58 million loss posted in the prior corresponding period, reflecting ongoing cost pressures and the challenges of scaling in competitive consumer nutrition markets. Revenue for the trailing twelve months was approximately AUD 24.27 million, giving the company a price-to-sales ratio of approximately 0.93x — a notably low valuation for a branded consumer goods business with genuine revenue and multi-market distribution infrastructure.

Today's 20% gain appears to reflect a combination of renewed speculative interest in the consumer defensive sector and bargain-hunting at historically low price levels, rather than any single specific corporate announcement.

Key Reasons Behind the Uptick

At AUD 0.12 per share and a market cap of just AUD 18.82 million against AUD 24 million in trailing revenue, NUC has attracted attention from value-oriented investors who see the current valuation as disconnected from the company's underlying commercial reality. The price-to-sales ratio of under 1x is unusual for a branded premium nutrition business with established channels across pharmacy, grocery, and e-commerce in both Australia and China.

Goat milk-based infant formula occupies a premium niche within the broader infant nutrition market — historically a high-demand, high-margin category in both domestic and Asian export markets. Nuchev's Oli6 brand has been in market for over a decade and carries genuine consumer recognition, particularly among parents seeking an alternative to standard cow milk formulas.

Key Growth Catalysts

Nuchev's key growth levers lie in its ongoing penetration of the Chinese and Vietnamese consumer markets, where rising middle-class demand for premium imported infant nutrition products continues to build. The bWellness acquisition adds a complementary distribution platform and broadens the revenue base beyond the core infant formula category into vitamins, dietary supplements, and broader health products.

The Oli6 brand's range — spanning infant formula, follow-on formula, toddler milk drink, and junior milk drink — gives the company multiple revenue touch points across the early childhood nutrition journey. Tightening operational costs and any improvement in the company's loss trajectory could act as meaningful catalysts for a re-rating, given the extremely low valuation relative to revenue.

Risks to Watch

Today's move should be viewed alongside the stark 12-month return of -25% — Nuchev has been unable to sustain price recoveries and has persistently traded lower over an extended period. The net loss of AUD 2.24 million for the most recent half-year represents a widening of losses, not a narrowing, which is a concerning trend. Return on equity stands at -38.03% and return on assets at -18.27%, reflecting the ongoing capital consumption required to support the business.

The Chinese consumer market for infant formula is intensely competitive and sensitive to regulatory changes, food safety sentiment, and shifting brand preferences. The company carries no dividend, no P/E ratio given persistent losses, and revenue for the trailing twelve months, while meaningful in absolute terms, has not been sufficient to generate profitability. NUC is not covered by any major institutional broker.